24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
GEMLIEVA RTU 1000 MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | GEMLIEVA RTU 1000 MG |
|---|---|
| Composition | Gemcitabine for Injection IP 1000mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
GEMLIEVA RTU 1000 MG (Gemcitabine for Injection IP 1000mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
GEMLIEVA 1000 MG (Gemcitabine for Injection IP 1000 mg) is a prescription anticancer medication containing Gemcitabine 1000 mg, a widely used chemotherapy medicine indicated for the treatment of various solid tumors and advanced cancers. Gemcitabine belongs to a class of medicines known as antimetabolites, which work by interfering with the DNA replication process of rapidly growing cancer cells, helping to slow or stop their growth and spread.
Cancer develops when abnormal cells multiply uncontrollably and invade surrounding tissues. These malignant cells require continuous DNA synthesis to grow and divide. Gemcitabine disrupts this process by incorporating itself into the DNA of cancer cells and preventing further replication. As a result, cancer cells lose their ability to multiply and eventually die.
GEMLIEVA 1000 MG is widely used in modern oncology and is considered an important treatment option for several types of cancer. It may be administered as a single-agent therapy or combined with other chemotherapy medicines depending on the type of cancer, stage of disease, and treatment objectives determined by the oncologist.
The medicine is commonly prescribed for:
Gemcitabine has become a key component of many cancer treatment regimens because of its proven clinical effectiveness and broad therapeutic applications. It is frequently used in patients with advanced disease where long-term disease control and symptom management are important treatment goals.
Manufactured according to stringent pharmaceutical quality standards, GEMLIEVA 1000 MG is designed to deliver consistent therapeutic performance, safety, and reliability.
Patients receiving Gemcitabine treatment typically require regular monitoring through blood tests, liver function assessments, kidney evaluations, and routine medical examinations to ensure treatment effectiveness and patient safety.
Due to its established role in cancer therapy, GEMLIEVA 1000 MG remains an essential medicine in modern oncology care worldwide.
GEMLIEVA 1000 MG (Gemcitabine for Injection IP 1000 mg) is primarily used for the treatment and management of various solid tumors and advanced cancers.
Gemcitabine is widely used as a standard treatment option for pancreatic cancer.
The medicine may be prescribed as part of treatment protocols for advanced lung cancer.
Doctors may include Gemcitabine in selected breast cancer treatment regimens.
The medicine is used in certain ovarian cancer treatment programs, particularly in recurrent disease.
Gemcitabine may be prescribed as part of chemotherapy protocols for bladder cancer.
The medicine may help manage cancers affecting the bile ducts and gallbladder.
GEMLIEVA is frequently administered with other anticancer medicines to improve treatment outcomes.
The medicine supports comprehensive oncology treatment strategies for various malignancies.
Gemcitabine belongs to a class of medicines known as Antimetabolites.
GEMLIEVA works by:
This targeted mechanism helps control cancer growth and supports effective disease management.
Like all chemotherapy medicines, GEMLIEVA 1000 MG may cause side effects in some patients. Side effects vary depending on dosage, treatment duration, and individual patient factors.
Weakness and tiredness are commonly reported during treatment.
Patients may experience mild to moderate nausea.
Episodes of vomiting may occur following treatment.
Mild fever may develop during therapy.
Reduced appetite may affect nutritional intake.
Temporary hair loss or hair thinning may occur in some patients.
Mild skin reactions may develop during treatment.
Some individuals may experience mild breathing difficulties.
The medicine may reduce:
This may increase the risk of infections, anemia, and bleeding complications.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of GEMLIEVA 1000 MG (Gemcitabine for Injection IP 1000 mg) should always be determined by a qualified oncologist or healthcare professional.
Different cancers require different treatment schedules and protocols.
Dosage is commonly calculated according to body size.
Laboratory test results help determine treatment suitability.
Organ function assessments may influence treatment planning.
Doctors may modify therapy based on effectiveness and patient tolerance.
Before receiving treatment, patients should inform their doctor if they have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant or breastfeeding women should only receive this medicine if specifically recommended by a healthcare professional.
It is used for the treatment of pancreatic cancer, lung cancer, breast cancer, ovarian cancer, bladder cancer, and other advanced solid tumors.
Gemcitabine is an antimetabolite chemotherapy medicine that interferes with DNA synthesis and helps prevent cancer cell growth.
Yes, it is a widely used chemotherapy medicine utilized in modern oncology treatment protocols.
Yes, it is frequently administered as part of combination chemotherapy regimens.
Yes, the medicine may lower blood cell counts, requiring regular laboratory monitoring.
Yes, reduced white blood cell counts may increase susceptibility to infections during treatment.
Yes, doctors typically recommend blood tests, liver and kidney assessments, and routine medical evaluations throughout therapy.
Yes, this medicine should only be administered by qualified healthcare professionals experienced in oncology, chemotherapy, and specialized cancer treatment.